SCHEMBL680282

SCHEMBL680282

O=[N+]([O-])c1ccc(Oc2cc3cnn(C4CCCCO4)c3cc2N2CCOCC2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MITF O75030 1/20 0.39
RAB9A P51151 1/20 0.39
ALDH1A1 P00352 4/20 0.39
NPC1 O15118 1/20 0.37
POLB P06746 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
RXRA P19793 1/20 0.36
RXRB P28702 1/20 0.36
RXRG P48443 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
EGFR P00533 1/20 0.36
MAPT P10636 1/20 0.36
ACHE P22303 1/20 0.35
ATR Q13535 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679462 0.86 RXRA (0.39) RAB9AALDH1A1NPC1POLBL3MBTL1
SCHEMBL679190 0.84 RXRA (0.43) RAB9AALDH1A1NPC1NPSR1L3MBTL1
SCHEMBL680373 0.84 EGFR (0.40) ALDH1A1L3MBTL1RXRARXRBRXRG
SCHEMBL680051 0.82 RXRA (0.42) RAB9AALDH1A1NPC1POLBNPSR1
SCHEMBL679314 0.82 RXRA (0.38) ALDH1A1L3MBTL1RXRARXRBRXRG
SCHEMBL679563 0.82 ALDH1A1 (0.38) ALDH1A1RXRARXRBRXRG
SCHEMBL679898 0.82 RXRA (0.38) ALDH1A1L3MBTL1RXRARXRBRXRG
SCHEMBL680305 0.81 PLK4 (0.39) ALDH1A1L3MBTL1RXRARXRBRXRG
SCHEMBL680011 0.81 RXRA (0.37) RAB9AALDH1A1NPC1POLBNPSR1
SCHEMBL680498 0.81 EGFR (0.37) MITFRAB9AALDH1A1NPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MITF 451/4885RAB9A 4028/4885ALDH1A1 1450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.